Robert W. Ross is on the board of Xilio Therapeutics, Inc. and Obsidian Therapeutics, Inc.

He previously occupied the position of President, Chief Executive Officer & Director at Surface Oncology, Inc. and Senior Vice President-Clinical Development at bluebird bio, Inc.

Robert W. Ross received an undergraduate degree from Stanford University, a graduate degree from Harvard Medical School and a graduate degree from Columbia University College of Physicians & Surgeons.